IN2014DN08325A - - Google Patents
Info
- Publication number
- IN2014DN08325A IN2014DN08325A IN8325DEN2014A IN2014DN08325A IN 2014DN08325 A IN2014DN08325 A IN 2014DN08325A IN 8325DEN2014 A IN8325DEN2014 A IN 8325DEN2014A IN 2014DN08325 A IN2014DN08325 A IN 2014DN08325A
- Authority
- IN
- India
- Prior art keywords
- amino acid
- antigens
- sequence
- difficile toxin
- residues
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 abstract 5
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 208000037384 Clostridium Infections Diseases 0.000 abstract 3
- 206010009657 Clostridium difficile colitis Diseases 0.000 abstract 3
- 206010054236 Clostridium difficile infection Diseases 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 101710084578 Short neurotoxin 1 Proteins 0.000 abstract 2
- 101710182223 Toxin B Proteins 0.000 abstract 2
- 101710182532 Toxin a Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91097—Hexosyltransferases (general) (2.4.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1206070.3A GB201206070D0 (en) | 2012-04-04 | 2012-04-04 | Clostridium difficile antigens |
| PCT/GB2013/050886 WO2013150309A1 (en) | 2012-04-04 | 2013-04-04 | Clostridium difficile antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08325A true IN2014DN08325A (enExample) | 2015-05-15 |
Family
ID=46160352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8325DEN2014 IN2014DN08325A (enExample) | 2012-04-04 | 2013-04-04 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9315555B2 (enExample) |
| EP (1) | EP2844283B1 (enExample) |
| JP (1) | JP2015516964A (enExample) |
| CN (1) | CN104755099A (enExample) |
| AU (1) | AU2013245412A1 (enExample) |
| BR (1) | BR112014024751A2 (enExample) |
| CA (1) | CA2869109A1 (enExample) |
| GB (1) | GB201206070D0 (enExample) |
| IN (1) | IN2014DN08325A (enExample) |
| SG (1) | SG11201406301TA (enExample) |
| WO (1) | WO2013150309A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103957931B (zh) * | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| MX2015017257A (es) | 2013-06-14 | 2016-11-11 | Sanofi Pasteur Inc | Composiciones y metodos de inmunizar contra clostridium difficile. |
| JP2018521967A (ja) * | 2015-05-15 | 2018-08-09 | サノフィ パストゥール インコーポレイテッド | クロストリジウム・ディフィシルに対する免疫方法 |
| CN109311950A (zh) * | 2016-03-21 | 2019-02-05 | 儿童医学中心公司 | 用于抑制wnt信号传导的组合物和方法 |
| CN112512556A (zh) | 2018-01-16 | 2021-03-16 | 儿童医学中心公司 | 用于抑制wnt信号传导的组合物和方法 |
| EP3880240A4 (en) * | 2018-11-16 | 2022-08-03 | Matrivax, Inc. | Clostridium difficile multi-component vaccine |
| WO2020231930A1 (en) * | 2019-05-11 | 2020-11-19 | The Texas A&M University System | Protein inhibitors of clostridium difficile toxin b |
| CA3141165A1 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Vaccine compositions for clostridium difficile |
| CN113717263B (zh) * | 2021-08-04 | 2022-06-07 | 河北医科大学第二医院 | 一种艰难梭菌特异性抗原肽 |
| CN118613492A (zh) * | 2022-01-30 | 2024-09-06 | 西湖大学 | Tfpi结合多肽及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| WO2000061762A1 (en) * | 1999-04-09 | 2000-10-19 | Techlab, Inc. | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
| WO2001094599A1 (en) | 2000-06-07 | 2001-12-13 | Smittskyddsinstitutet | Gene expression cassette and its use |
| GB0205206D0 (en) | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| SI2857418T1 (en) | 2004-02-06 | 2018-01-31 | University Of Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
| EP2054044B1 (de) | 2006-08-02 | 2014-07-23 | Johannes Gutenberg-Universität Mainz | Arzneimittel gegen lct-vergiftungen |
| US8889363B2 (en) | 2009-07-27 | 2014-11-18 | Biodics | Method for the detection and identification of a variant C. difficile strain in a sample |
| MX339253B (es) | 2010-04-15 | 2016-05-18 | Progenics Pharm Inc | Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile. |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
-
2012
- 2012-04-04 GB GBGB1206070.3A patent/GB201206070D0/en not_active Ceased
-
2013
- 2013-04-04 IN IN8325DEN2014 patent/IN2014DN08325A/en unknown
- 2013-04-04 AU AU2013245412A patent/AU2013245412A1/en not_active Abandoned
- 2013-04-04 CA CA2869109A patent/CA2869109A1/en not_active Abandoned
- 2013-04-04 BR BR112014024751A patent/BR112014024751A2/pt not_active IP Right Cessation
- 2013-04-04 WO PCT/GB2013/050886 patent/WO2013150309A1/en not_active Ceased
- 2013-04-04 EP EP13715732.7A patent/EP2844283B1/en active Active
- 2013-04-04 US US14/390,528 patent/US9315555B2/en active Active
- 2013-04-04 CN CN201380029315.2A patent/CN104755099A/zh active Pending
- 2013-04-04 JP JP2015503943A patent/JP2015516964A/ja not_active Withdrawn
- 2013-04-04 SG SG11201406301TA patent/SG11201406301TA/en unknown
-
2016
- 2016-04-15 US US15/130,749 patent/US9896514B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014024751A2 (pt) | 2017-07-11 |
| US20160319037A1 (en) | 2016-11-03 |
| CA2869109A1 (en) | 2013-10-10 |
| AU2013245412A1 (en) | 2014-10-16 |
| WO2013150309A9 (en) | 2015-04-09 |
| SG11201406301TA (en) | 2014-11-27 |
| GB201206070D0 (en) | 2012-05-16 |
| US20150093389A1 (en) | 2015-04-02 |
| US9315555B2 (en) | 2016-04-19 |
| WO2013150309A8 (en) | 2014-12-24 |
| EP2844283A1 (en) | 2015-03-11 |
| CN104755099A (zh) | 2015-07-01 |
| US9896514B2 (en) | 2018-02-20 |
| EP2844283B1 (en) | 2019-06-12 |
| HK1202805A1 (en) | 2015-10-09 |
| JP2015516964A (ja) | 2015-06-18 |
| WO2013150309A1 (en) | 2013-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08325A (enExample) | ||
| WO2012046061A3 (en) | Clostridium difficile antigens | |
| MX2020003260A (es) | Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso. | |
| ZA202200648B (en) | Immunoglobulins and uses thereof | |
| IN2014KN01715A (enExample) | ||
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| SG10201811172PA (en) | A peptide mixture | |
| EP4296673A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| CY1119916T1 (el) | Ανοσογονικη συνθεση | |
| MX384984B (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| EA201390820A1 (ru) | Слитый белок против рака | |
| MX387560B (es) | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| AU2015255979B2 (en) | Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses | |
| PH12020552222A1 (en) | Immunodominant proteins and fragments in multiple sclerosis | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| MX389320B (es) | Anticuerpos anti-tnfrsf25 | |
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| MX2016008305A (es) | Combinaciones de peptidos y usos de los mismos en tratar alergia al acaro del polvo. | |
| MX2019006446A (es) | Métodos para inducir tolerancia inmunológica a factores de coagulación. | |
| MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
| NZ700199A (en) | Epsilon toxin epitopes from clostridium perfringens with reduced toxicity | |
| MX2017016438A (es) | Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit. |